Cognition and Communication in Patients with Spinal Muscular Atrophy: A Systematic Review

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Jul 23

PMID 39040255

Authors

Sanae Akodad

Delphine De Smedt

Simon Baijot

Hilde Stevens

Nicolas Deconinck

Affiliations

Soon will be listed here.

Abstract

•Synthesizes evidence from 12 studies on cognitive and communicative impacts in SMA, focusing on nuanced functional outcomes.•Highlights cognitive variability in SMA1, revealing subtle challenges in SMA2 and 3, and stresses tailored assessment methodologies.•Identifies communication barriers in SMA, emphasizing the urgency of investigating their potential interplay with cognitive functions.•Stresses integrating cognitive and communicative assessments into SMA management, to enhanceunderstanding of treatment impacts.•Calls for standardized, sensitive tools to evaluate cognition and communication, ensuring consistent assessments across SMA phenotypes.

References

Mercuri E, Pera M, Scoto M, Finkel R, Muntoni F . Spinal muscular atrophy - insights and challenges in the treatment era. Nat Rev Neurol. 2020; 16(12):706-715. DOI: 10.1038/s41582-020-00413-4. View

Polido G, de Miranda M, Carvas N, Mendonca R, Caromano F, Reed U . Cognitive performance of children with spinal muscular atrophy: A systematic review. Dement Neuropsychol. 2019; 13(4):436-443. PMC: 6907703. DOI: 10.1590/1980-57642018dn13-040011. View

Masson R, Brusa C, Scoto M, Baranello G . Brain, cognition, and language development in spinal muscular atrophy type 1: a scoping review. Dev Med Child Neurol. 2021; 63(5):527-536. DOI: 10.1111/dmcn.14798. View

Aragon-Gawinska K, Mouraux C, Dangouloff T, Servais L . Spinal Muscular Atrophy Treatment in Patients Identified by Newborn Screening-A Systematic Review. Genes (Basel). 2023; 14(7). PMC: 10379202. DOI: 10.3390/genes14071377. View

Mix L, Schreiber-Katz O, Wurster C, Uzelac Z, Platen S, Gipperich C . Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA). Orphanet J Rare Dis. 2021; 16(1):10. PMC: 7789267. DOI: 10.1186/s13023-020-01661-9. View

Al-Zaidy S, Pickard A, Kotha K, Alfano L, Lowes L, Paul G . Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol. 2018; 54(2):179-185. PMC: 6590370. DOI: 10.1002/ppul.24203. View

Tosi M, Cumbo F, Catteruccia M, Carlesi A, Mizzoni I, Luca G . Neurocognitive profile of a cohort of SMA type 1 pediatric patients and emotional aspects, resilience and coping strategies of their caregivers. Eur J Paediatr Neurol. 2023; 43:36-43. DOI: 10.1016/j.ejpn.2023.02.004. View

Dubowitz V . Chaos in classification of the spinal muscular atrophies of childhood. Neuromuscul Disord. 1991; 1(2):77-80. DOI: 10.1016/0960-8966(91)90051-s. View

Ball L, Chavez S, Perez G, Bharucha-Goebel D, Smart K, Kundrat K . Communication skills among children with spinal muscular atrophy type 1: A parent survey. Assist Technol. 2019; 33(1):38-48. DOI: 10.1080/10400435.2019.1586788. View

10.

Savad S, Ashrafi M, Samadaian N, Heidari M, Modarressi M, Zamani G . A comprehensive overview of SMN and NAIP copy numbers in Iranian SMA patients. Sci Rep. 2023; 13(1):3202. PMC: 9957985. DOI: 10.1038/s41598-023-30449-7. View

11.

Zerres K, Rudnik-Schoneborn S, Rohrig D, Wirth B . [Spinal muscular atrophy in childhood. Possibilities and limits of clinical and molecular genetic diagnosis]. Monatsschr Kinderheilkd. 1993; 141(11):848-54. View

12.

Kizina K, Akkaya Y, Jokisch D, Stolte B, Totzeck A, Munoz-Rosales J . Cognitive Impairment in Adult Patients with 5q-Associated Spinal Muscular Atrophy. Brain Sci. 2021; 11(9). PMC: 8471736. DOI: 10.3390/brainsci11091184. View

13.

Mirea A, Shelby E, Axente M, Badina M, Padure L, Leanca M . Combination Therapy with Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type I. J Clin Med. 2021; 10(23). PMC: 8658131. DOI: 10.3390/jcm10235540. View

14.

Lenzoni S, Semenza C, Calligaro D, Turcano P, Caumo L, Pegoraro E . Cognitive profiles and clinical factors in type III spinal muscular atrophy: a preliminary study. Neuromuscul Disord. 2022; 32(8):672-677. DOI: 10.1016/j.nmd.2022.05.005. View

15.

Osmanovic A, Wieselmann G, Mix L, Siegler H, Kumpe M, Ranxha G . Cognitive Performance of Patients with Adult 5q-Spinal Muscular Atrophy and with Amyotrophic Lateral Sclerosis. Brain Sci. 2020; 11(1). PMC: 7822456. DOI: 10.3390/brainsci11010008. View

16.

Vidovic M, Freigang M, Aust E, Linse K, Petzold D, GuNTHER R . Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen. BMC Neurol. 2023; 23(1):216. PMC: 10243018. DOI: 10.1186/s12883-023-03261-z. View

17.

Strauss K, Farrar M, Muntoni F, Saito K, Mendell J, Servais L . Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial. Nat Med. 2022; 28(7):1381-1389. PMC: 9205281. DOI: 10.1038/s41591-022-01866-4. View

18.

Ngawa M, Dal Farra F, Marinescu A, Servais L . Longitudinal developmental profile of newborns and toddlers treated for spinal muscular atrophy. Ther Adv Neurol Disord. 2023; 16:17562864231154335. PMC: 9944336. DOI: 10.1177/17562864231154335. View

19.

Zappa G, LoMauro A, Baranello G, Cavallo E, Corti P, Mastella C . Intellectual abilities, language comprehension, speech, and motor function in children with spinal muscular atrophy type 1. J Neurodev Disord. 2021; 13(1):9. PMC: 7856807. DOI: 10.1186/s11689-021-09355-4. View

20.

Schorling D, Pechmann A, Kirschner J . Advances in Treatment of Spinal Muscular Atrophy - New Phenotypes, New Challenges, New Implications for Care. J Neuromuscul Dis. 2019; 7(1):1-13. PMC: 7029319. DOI: 10.3233/JND-190424. View